SHARE NOW
Charles River Laboratories International has announced that it is to launch its propriety Adeno-Associated Virus (AAV) vector platform – nAAVigation – at this year’s Cell and Gene Meeting on the Mesa.
The Companies Senior Director and Global Head of Commercial Gene Therapy CDMO Services, Ramin Baghirzade will outline how this platform will accelerate its gene therapy manufacturing programs in the session ‘nAAVigationTM Vector Platform: Accelerating Your AAV Pathway to GMP and Clinic’ on Wednesday 12th Oct.
Built from years of AAV vector CDMO experience, expertise, and testing, the nAAVigation platform will streamline GMP AAV vector manufacturing. This will allow GMP viral vector gene therapy developers to reduce their timelines by up to 55%, compared to traditional manufacturing workflows.
nAAVigation accelerates the time to clinic to less than eight months by leveraging established developmental processes, template documents, on-hand materials, and 100% qualified, in-house analytics.
“The significant turnaround time reduction for viral vector therapy developers utilizing nAAVigation combined with Charles River’s established development process, standard, on-hand materials, templated documents, and in-house analytics will enhance our clients’ experiences,” said Professor Daniel Smith, Executive Director Global Cell and Gene Therapy Portfolio, Charles River.
How are you enjoying this news article? Let us know your thoughts, here >>
The nAAVigation platform is based upon the proprietary high-productivity HEK293 suspension cell line and couples an optimized single-use upstream system with a robust downs-stream purification process, enabling clients the capacity to scale-up to 500L in suspension.
This launch enhances Charles River’s extensive cell and gene therapy end-to-end support and supply chain simplification offerings to its expanding ATMP portfolio.
“The launch of the nAAVigation Vector Platform process is the latest in a series of portfolio enhancements aimed at supporting our cell and gene therapy clients from early target identification through clinical-stage manufacturing. By increasing speed and efficiency for viral vector production, nAAVigation will help accomplish our ultimate goal of delivering safe, effective therapies to patients faster,” commented Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, Charles River.
Source: Charles River Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
